Masimo CorporationMASINASDAQ
Loading

Latest News

Harbor Health Care ETF Q4 2025 Portfolio Review
seekingalpha.com

Harbor Health Care ETF Q4 2025 Portfolio Review

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.

American Century Companies Inc. Boosts Position in Masimo Corporation $MASI
defenseworld.net

American Century Companies Inc. Boosts Position in Masimo Corporation $MASI

American Century Companies Inc. raised its holdings in shares of Masimo Corporation (NASDAQ: MASI) by 10.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 168,341 shares of the medical equipment provider's stock after acquiring an additional 16,113 shares

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
businesswire.com

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

What's Happening With Masimo Stock?
forbes.com

What's Happening With Masimo Stock?

Masimo stock (MASI) has faced a challenging year, trailing the broader market with a -3% annual return. While shares surged 34% yesterday following news of an acquisition by Danaher, this spike only partially offsets a period of long-term stagnation.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Masimo Corporation (NASDAQ: MASI)
prnewswire.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Masimo Corporation (NASDAQ: MASI)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Masimo Corporation (NASDAQ: MASI) related to its sale to Danaher Corporation.